Brief: Prelude Therapeutics Receives FDA Clearance Of Ind For Prt3789
18/10/2022 13:17
Oct 18 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS RECEIVES FDA CLEARANCE OF IND FOR
PRT3789,
A POTENT AND SELECTIVE FIRST-IN-CLASS SMARCA2 PROTEIN DEGRADER
* COMPANY ANTICIPATES DOSING THE FIRST PATIENT IN Q1 OF 2023
Source text for Eikon: ID:nGNXHm58q
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview